NPM1突变急性髓系白血病的真实世界结局:可测量残留病对疾病复发的影响
结果显示第二周期化疗后0.1%阈值可有效分层复发风险并可能指导移植决策,随访中0.01%阈值可预测6个月复发风险。
要点
- 第二周期化疗后MRD<0.1%者,CR1期异基因移植未改善RFS或OS。
- 随访中MRD≥0.1%需早期干预以避免 imminent 复发。
- MRD≥0.01%且<0.1%者需密切监测,因进展为高水平MRD风险高。
核心结论
- 第二周期化疗后骨髓MRD阈值0.1%可分层复发风险并可能指导移植决策。
- 随访中MRD阈值0.01%可预测6个月复发风险并指导临床管理。
研究设计与样本
- 患者第二周期诱导后达CR/CRi,采用RT-qPCR检测骨髓MRD。
主要发现
- 第二周期化疗后MRD<0.1%者,CR1期异基因移植未显示RFS或OS差异。
- 随访中高水平MRD阳性(≥0.1%)需早期干预以避免即将发生的复发。
- MRD不可测或极低水平(<0.01%)者可安全监测无需进一步干预。
- 低水平MRD阳性(≥0.01%且<0.1%)者进展为高水平MRD风险高,需密切监测。
关键数值与推荐
- 第二周期化疗后MRD阈值0.1%(mutNPM1/ABL)用于风险分层和移植决策。
- 随访中MRD阈值0.01%(mutNPM1/ABL)预测6个月复发风险。
临床怎么用
- 第二周期化疗后检测骨髓NPM1突变MRD,以0.1%为阈值评估移植必要性。
- 随访中监测MRD,≥0.1%考虑早期干预,<0.01%可安全监测,中间水平密切随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognostic value of NPM1-mut Measurable Residual Disease (MRD) has been increasingly recognized. However, real-world data validating the prognostic impact of NPM1-mut MRD remains limited. The aim of this study was to assess the prognostic value of NPM1-mut MRD and to explore optimal MRD thresholds for relapse prediction. One hundred forty-one patients with newly diagnosed NPM1-mut AML, from the Hellenic AML-Registry, in CR/CRi after the second cycle of induction and with bone marrow (BM) MRD assessment by RT-qPCR, were included in our study. Allogeneic stem cell transplantation (allo-SCT) in CR1 was not associated with any difference in RFS or OS between patients who achieved < 0.1% mutNPM1/ABL after the second cycle of chemotherapy, suggesting that this cut-off may effectively stratify relapse risk and possibly guide optimal use of allo-SCT. End-of-treatment (EOT) and during follow-up MRD assessment exhibited equally significant prognostic value, with high-level MRD positivity (≥ 0.1% mutNPM1/ABL) requiring early intervention to avoid imminent relapse, while those with undetectable or very low-level MRD (< 0.01% mutNPM1/ABL) being able to be safely monitored with no further intervention. Patients with low-level MRD positivity (≥ 0.01% and < 0.1%) require close MRD monitoring due to the substantial risk for progression to high-level MRD positivity. Overall, our results confirm the prognostic value of MRD assessment in BM samples at certain time points, with the cut-off of 0.1% after two cycles of chemotherapy enabling risk stratification and possibly informing transplant decisions, and during follow-up the cut-off of 0.01% being able to predict the 6-month relapse risk and guide further clinical management.
引用
- Tsirigotis P, Garofalaki M, Lazana I, et al. Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse. Am J Hematol. 2026. PMID: 41960888. doi:10.1002/ajh.70322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。